About us 

Crucell products

Crucell focuses on developing and marketing vaccines and antibodies against a range of infectious diseases in the paediatric, travel and endemic fields. We currently have a product portfolio of vaccines against major infectious diseases, such as influenza, hepatitis A, hepatitis B and typhoid fever.


Vaccines play a vital role in protecting against disease and have contributed significantly to the improvement of global public health in the twentieth century. Smallpox was eradicated through the use of vaccines. Significant advances include the introduction of combination vaccines and the development of new vaccine technologies.


In 2010, a Crucell vaccine was given to 190 people every minute.1 Over the full year, more than 105 million doses of vaccines were distributed in more than 100 countries, thereby preventing more than 3.6 million cases of infectious disease and over 809,000 deaths that would otherwise have occurred.


In this section, you will find information about Crucell’s marketed products and comprehensive information about the diseases each of these vaccines is designed to prevent.


1 Figures based on Crucell’s top 5 vaccines Quinvaxem®, Hepavax-Gene®, Epaxal®, Vivotif®
and Inflexal® V. Total 101,666,000 doses minus 2% waste (2,033,320 doses) = 99,632,680
doses sold in 2010 / 525600 minutes in 2010 = 189.5598 doses administered per minute.


-   Fully liquid vaccine to protect against five important childhood diseases
- Recombinant hepatitis B vaccine
- Low dosage, aluminum-free hepatitis A vaccine (0.25ml)


Travel and endemic:

- Aluminum-free hepatitis A vaccine
- Oral typhoid vaccine
- Only internationally licensed oral vaccine against cholera (and ETEC)   



- Virosomal adjuvanted influenza vaccine (all age groups)



1 Figures based on Crucell Quinvaxem®, Hepavax-Gene®, Inflexal® V and Vivotif® vaccines.



Crucell®, Quinvaxem®, Hepavax-Gene®, Epaxal®, Vivotif®, Dukoral® and Inflexal® V are registered trademarks of the Crucell group.

© Crucell 2009 | Disclaimer